| Previous Close | 4.6100 |
| Open | 4.6806 |
| Bid | 4.56 x 1400 |
| Ask | 4.94 x 900 |
| Day's Range | 4.2400 - 4.6029 |
| 52 Week Range | 2.5300 - 5.6500 |
| Volume | 88,987 |
| Avg. Volume | 98,930 |
| Market Cap | 54.18M |
| Beta (3Y Monthly) | 2.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 |
| Earnings Date | Nov 8, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Accumulation is close to an all-time high, signaling strong speculative interest. A cup and handle breakout would yield an impressive measured move target near $9.50, which is close to a 2015 breakdown into single digits.
MTBC (MTBC) (MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced that Chief Executive Officer, Stephen Snyder, and Chief Financial Officer, Bill Korn, will present at the 11th annual LD Micro Main Event at the Luxe Sunset in Bel-Air, California. The Company's presentation will take place on Tuesday, December 4, 2018 at 4:00-4:30 PM Pacific Time. The Company will update investors on its progress during 2018, a year when revenue is on track to grow by more than 50% from 2017, while adjusted EBITDA is expected to grow by approximately 100%.
Q3 2018 Medical Transcription Billing Corp Earnings Call
Medical Transcription Billing Corp (MTBC) reported financial results for their third quarter 2018 and provided a business update. Financial performance is already benefitting from the transaction with Q3 setting new record highs in revenue, revenue growth and consecutive quarters (i.e.
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Company Reports Historic Revenue Growth, on Track for Record Year ●Revenue of $17.0 million for Q3 2018, a 127% increase over Q3 2017 ●Revenue of $34.0 million for YTD 2018, a.
MTBC (MTBC) (MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced that its Board of Directors has declared monthly cash dividends for its 11% Series A Cumulative Redeemable Perpetual Preferred Stock ("Series A Preferred Stock") for December 2018, January 2019 and February 2019. This represents 40 consecutive months of dividends declared since the Series A Preferred Stock was initially sold in November 2015. Holders of shares of the Series A Preferred Stock are entitled to receive cumulative cash dividends at the rate of 11% per annum of the $25.00 per share liquidation preference (equivalent to $2.75 per annum per share).
Penny stocks got battered and bruised during the month of October, undermined by a broad-based retreat that dropped the Russell 2000 small-cap index to an eight-month low. The broad market could post new lows in early November, but a profitable relief rally should unfold in coming weeks, favoring dip trades on penny stocks that have held technical support levels through the maelstrom. This month's penny stock list includes several of these plays, but it's important to think and act defensively, placing stop losses immediately after entry. Penny Stock Picks to Buy Using Technical Analysis for November 1.
MTBC (MTBC) (MTBCP), a leading provider of proprietary, cloud-based healthcare IT and practice management solutions today announced that it has entered into a new group purchasing contract with one of the world’s top five pharmaceutical manufacturers. This new affiliation will allow the members of MTBC’s group purchasing organization (GPO) to purchase critical vaccines for their practices at a negotiated discount.
MTBC (MTBC) (MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, will release its financial results for the nine months ended September 30, 2018 before the market opens on Wednesday, November 7, 2018. The Company will follow with a conference call for investors at 8:30 a.m. ET, during which management will review highlights of the third quarter 2018. Management will provide updates regarding the Company's progress toward achieving its full year revenue and adjusted EBITDA guidance, which represent year-over-year growth of more than 50% and 70% respectively.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MTBC (the "Company") (MTBC) (MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced the successful closing of its largest offering to date of its non-convertible 11% Series A Cumulative Redeemable Perpetual Preferred Stock ("Series A Preferred Stock"), comprised of 600,000 additional shares at a price of $25 per share, for gross proceeds of $15 million. The shares of preferred stock were sold pursuant to a registration statement on Form S-1 (File No. 333-227524) that was declared effective by the Securities and Exchange Commission (the "SEC") on October 10, 2018 and an additional registration statement on Form S-1 (File No. 333-227777) filed pursuant to Rule 462(b), which became automatically effective on October 10, 2018.
If you’re interested in Medical Transcription Billing Corp (NASDAQ:MTBC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock Read More...
MTBC (the "Company") (MTBC) (MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced the sale in an upsized public offering of approximately 600,000 additional shares of its non-convertible 11% Series A Cumulative Redeemable Perpetual Preferred Stock ("Series A Preferred Stock") at a price of $25 per share, for gross proceeds of approximately $15.0 million. H.C. Wainwright & Co. is acting as exclusive lead placement agent for the offering. After deducting placement agent's fees and other offering expenses payable by MTBC, the net proceeds to MTBC are anticipated to be approximately $13.3 million.
The Digital Issue of the Fall 2018 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / October 9, 2018 / SNN ...
Blue chips led broad price action in September, lifting the S&P 500 and the Dow Jones Industrial Average to bull market highs while small cap indices such as the Russell 2000 pulled back in shallow declines. Penny and low-priced stocks held up well during the month despite this headwind, with traders scooping up junior energy plays in reaction to a surging crude oil market. Penny stock buyers have taken notice, lifting the shares of low-priced American oil and gas companies still reeling from the group's historic decline into 2016.
MTBC (MTBC) (MTBCP), a leading provider of revenue cycle and cloud-based healthcare IT solutions, today announced that Silicon Valley Bank (SIVB), the bank of the world's most innovative companies and their investors, has increased its secured line of credit, which is currently untapped, to $10 million to support future growth. "In the year since we started working with MTBC, it has been great to watch them complete the integration of MediGain, double their adjusted EBITDA, and strengthen their balance sheet," said Tom Gordon, Managing Director of Silicon Valley Bank. "MTBC positioned themselves to be ready for another major acquisition, and they moved quickly when they saw an opportunity with Orion.
SOMERSET, N.J., Sept. 18, 2018-- MTBC, a leading provider of proprietary, cloud-based healthcare IT and practice management solutions has been recognized as one of the“ Top 10 RCM Solution Providers- 2018” ...
Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.
This upwardly revised guidance is well ahead of the $42.3M in revenue and $3.6M in adjusted EBITDA that we had been modeling for 2018 following the announced-close of the Orion acquisition in early July. Updates to our model have resulted in calculated fair value of MTBC common stock moving from $7.10/share (previously) to $10.0/share (currently). In fact, excluding Q4 ’16 which benefitted from one-time sales following close of the MediGain acquisition, Q1 and Q2 2018 set new quarterly revenue records.
Q2 2018 Medical Transcription Billing Corp Earnings Call